SkinBioTherapeutics PLC
LSE:SBTX

Watchlist Manager
SkinBioTherapeutics PLC Logo
SkinBioTherapeutics PLC
LSE:SBTX
Watchlist
Price: 13.5 GBX -10.74%
Market Cap: 34.9m GBX

SkinBioTherapeutics PLC
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

SkinBioTherapeutics PLC
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
SkinBioTherapeutics PLC
LSE:SBTX
Research & Development
-ÂŁ327.1k
CAGR 3-Years
22%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Research & Development
-$150.2m
CAGR 3-Years
-16%
CAGR 5-Years
-104%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Research & Development
-$238.3m
CAGR 3-Years
-51%
CAGR 5-Years
-52%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Research & Development
-ÂŁ222.2m
CAGR 3-Years
-45%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Research & Development
-ÂŁ15.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
6%
Oxford BioMedica PLC
LSE:OXB
Research & Development
ÂŁ9.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

SkinBioTherapeutics PLC
Glance View

Market Cap
34.9m GBX
Industry
Biotechnology

SkinBioTherapeutics Plc is a life science company, which focuses on skin health. The company is headquartered in Macclesfield, Cheshire and currently employs 7 full-time employees. The company went IPO on 2017-04-05. The firm is targeting a number of skin healthcare sectors, which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis, medical device applications and others. The Company’s platform technology, SkinBiotix, is designed to promote skin health by harnessing the beneficial properties of probiotic bacteria and the active components derived from them. SkinBiotix protects the skin from infection and increases the rate of skin healing in response to injury. The firm's AxisBiotix technology is based on the emerging area of science that is focused on the gut-skin axis and the constitution of the gut microbiome plays a role in various diseases, such as psoriasis. AxisBiotix-Ps is the product developed by the Company that uses the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.

SBTX Intrinsic Value
22.76 GBX
Undervaluation 41%
Intrinsic Value
Price

See Also

What is SkinBioTherapeutics PLC's Research & Development?
Research & Development
-327.1k GBP

Based on the financial report for Dec 31, 2024, SkinBioTherapeutics PLC's Research & Development amounts to -327.1k GBP.

What is SkinBioTherapeutics PLC's Research & Development growth rate?
Research & Development CAGR 5Y
16%

Over the last year, the Research & Development growth was 55%. The average annual Research & Development growth rates for SkinBioTherapeutics PLC have been 22% over the past three years , 16% over the past five years .

Back to Top